"There are three things all wise men fear: the sea in storm, a night with no moon, and the anger of a gentle man." ? Patrick Rothfuss, The Wise Man's Fear
Today we look at Acceleron Pharma (NASDAQ:XLRN). A Biotech Forum subscriber inquired late in the week whether the recent dip in the stock is a buying opportunity. Let's take a look.
Company Overview:
Acceleron Pharma is a Boston based clinical stage "Tier 4" biopharmaceutical company that is focusing on the development and commercialization of therapeutics for serious and rare diseases. The company came public in 2013 and has a market capitalization of nearly $1 billion. The stock now sells for just over $25 a share and could be termed a "Busted IPO" as this is roughly half the level the shares had achieved soon after their debut. Despite the company's market size and a collaboration deal with Celgene (NASDAQ:CELG), Acceleron does not receive much attention. The last solely focused article on it on SeekingAlpha was in September of last year.
